Comparative analysis of hepatitis B virus infections in blood donors born before and after the implementation of universal HBV vaccination in southern China. Issue 1 (16th August 2022)

• Record Type: Journal Article
• Authors: Ye, Xianlin; Li, Tong; Li, Yi; Zeng, Jinfeng; Li, Ran; Xu, Xiaoxuan; Guan, Xiaoyu; Li, Ling
• Is Part Of: Transfusion medicine. Volume 33:Issue 1(2023)
• Page Start: 81
• Page End: 89
• Publication Date: 2022-08-16
• Subjects: blood donors -- hepatitis B virus -- mutations -- the universal HBV vaccination program; Blood -- Transfusion -- Periodicals; 615.39
• DOI: 10.1111/tme.12903
• Languages: English
• ISSNs: 0958-7578

Abstract

Abstract: Background: In China, the vaccinated blood donors have rapidly increased by recent years, which may impact blood safety. The true prevalence of HBV between vaccinated blood donors and non‐vaccinated blood donors should be explored. Study Design and Methods: The samples of blood donors were collected and detected for serologic markers of HBV in the Shenzhen Blood Centre (SZBC). The discrepant results were tested with commercial electrochemiluminescence immunoassay (ELCI) for HBsAg, anti‐HBs, HBeAg, Anti‐HBe and Anti‐HBc, alternative MPX ID NAT, nested PCR, and a quantitative real‐time polymerase chain reaction (qPCR) assay for HBV DNA. The serological and molecular characteristics of HBV infected blood donors were analysed, and the effects on blood safety for donors born before and after the implementation of universal HBV vaccination were compared. Results: Out of 242 presumed HBV infected donors from 26 318 donations, 131 (0.49%, [95% CI, 0.43–0.59]) chronic HBV infections (CHB, HBsAg detected with or without DNA), 58 (0.22%, [95% CI, 0.17–0.28]) occult hepatitis B infections (OBI, HBsAg not detected, assume anti‐HBc positive and/or anti‐HBs with HBV DNA) and 3 (0.011%, [95% CI, 0.0023–0.033]) window period (WP) infections were confirmed respectively. There were 28 CHBs (0.44%), 7 OBIs (0.11%) and 1 WP (0.016%) from vaccinated blood donor and 103 CHBs (0.52%), 51 OBIs (0.26%) and 2 WPs (0.01%) from non‐vaccinated blood donor. The HBV+ (CHBs, OBIs and WPs) rate (0.56%) in vaccinated donors was lower than in non‐vaccinated donors (0.78%, p < 0.05). The HBsAg titers of vaccinated infected blood donors (Median: 128.8 IU/ml) were much higher than non‐vaccinated infected blood donors (58.4 IU/ml). The OBI yield rates in the vaccinated blood donors was significantly lower than the non‐vaccinated blood donors ( p < 0.05). There 102/124 (82.3%) samples were genotype B, 22/124 (17.7%) were genotype C respectively. There was no significant difference in the distribution of genotype between non‐vaccinated blood donors (B/C, 86/17) and vaccinated blood donors (B/C, 23/6; p > 0.05). High frequency of vaccine escape mutations M133L (32.4%) and E164G in S region of genotype B strains and substitution L175S (40.9%) related to vaccine escape in S region of genotype C strains were identified. Conclusion: The universal HBV vaccination program markedly reduces the risk of HBV infection in blood donors, and provides a significant guarantee for the safety of blood transfusion. Several important mutations detected related vaccine escape and notable mutations needed further investigated.